Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 15, 2008

Genzyme to Pursue Prognostic Test for NSCLC with License from Moffitt

  • Genzyme obtained exclusive, worldwide diagnostic testing rights from Moffitt Cancer Center to its discovery of two proteins linked to non-small-cell lung cancer (NSCLC) treatment response. Genzyme plans on developing a test that can be used to guide first-line treatment of platinum drugs and gemcitabine.

    Gerold Bepler, M.D., reportedly showed that the expression levels of two proteins, RRM1 and ERCC1, correlate with patient response to platinum drugs and gemcitabine. Through this license, Genzyme plans to develop and market a test that can be used to measure the expression levels of these proteins in NSCLC patients.

    Genzyme will make milestone payments to Moffitt. The company will also provide running royalties on the sales of licensed services and products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »